Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
WuXi Diagnostics logo — A next-generation integrated diagnostic enabling platform

WuXi Diagnostics

A next-generation integrated diagnostic enabling platform

Founded 2018 China Shanghai, China 46 employees Series B Total: $150.00M Biotechnology, Health Care +1

General Information

Company Name WuXi Diagnostics
Founded Year 2018
Location China Shanghai, China
Employees 46
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with WuXi Diagnostics. To contact WuXi Diagnostics, visit wuxidiagnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does WuXi Diagnostics compare?

A PDF of WuXi Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting WuXi Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About WuXi Diagnostics

WuXi Diagnostics (WXDX) is a groundbreaking biotechnology company founded in 2018 with a vision to revolutionize healthcare through its next-generation integrated diagnostic enabling platform. With headquarters in Shanghai, China, it boasts a CAP-accredited Independent Clinical Laboratory and a production facility of In Vitro Diagnostic reagent kits and instruments in Suzhou, along with an R&D center at Mayo Clinic headquarters in Rochester, U.S. The company's flagship product, Enabling Solution Package (ESP), is a comprehensive solution designed to enhance healthcare practice and advance patient care. It encompasses advanced testing panels, medical paradigms, and algorithms for disease diagnosis, coupled with insightful medical content grounded in real-world clinical evidence. ESPs play a pivotal role across four stages of disease management: screening & early diagnosis, precision diagnosis, clinical decision support, and prognosis management. WXDX's dual enabling platforms for specialized testing service and medical innovation are at the forefront of driving precision diagnosis in China while spearheading the development of a new ecosystem for next-generation diagnostics. With a recent Series B investment of $150.00M secured on 23 February 2021, Shiyu Capital, Sunland Capital, YF Capital, Thermo Fisher Scientific, ABC International, CCBI Tech Venture have demonstrated their confidence in the company's potential for growth and impact in the healthcare sector.

Business keywords: Integrated Diagnostic, Diagnostic Platform, R&D Center, In Vitro Diagnostic, Clinical Laboratory, Precision Diagnosis, Medical Innovation, Disease Management, Diagnostic Solutions, Multidisciplinary Technology, Clinical Evidence, Medical Algorithms, Medical Content, Healthcare Ecosystem

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $150.00M 6
Shiyu Capital Sunland Capital
Shiyu Capital, Sunland Capital +4
23 Feb 2021
Series A Undisclosed 1
YF Capital
01 Jan 2019

WuXi Diagnostics Alternatives & Competitors

View All Alternatives
WuXi Diagnostics vs
Molecular Testing Labs
Molecular Testing Labs United States

Powering Health Diagnostics

168 employees
Biotechnology, Health Care
Compare WuXi Diagnostics vs Molecular Testing Labs
WuXi Diagnostics vs
Anumana
Anumana United States

Unlocking the Language of the Heart & Transforming Cardiac Care Through Cutting-Edge AI Solutions

Series C
88 employees
AI, Health Care
Compare WuXi Diagnostics vs Anumana
WuXi Diagnostics vs
Cleveland HeartLab, Inc.
Cleveland HeartLab, Inc. United States

Specializing in next-generation cardiovascular disease prevention, diagnosis & management and inflam...

Venture round
63 employees
Biotechnology, Health Care
View all alternatives

FAQ About WuXi Diagnostics

A next-generation integrated diagnostic enabling platform
WuXi Diagnostics was founded in 2018.
WuXi Diagnostics is headquartered in Shanghai, China.
WuXi Diagnostics operates in Biotechnology, Health Care and Medical Devices. Its work centres on Integrated Diagnostic, Diagnostic Platform, R&D Center and In Vitro Diagnostic.
WuXi Diagnostics has approximately 46 employees.
WuXi Diagnostics has completed 2 funding rounds, raising a total of $150.00M. The latest funding stage is Series B.
Top alternatives and competitors to WuXi Diagnostics include Molecular Testing Labs, Anumana, Cleveland HeartLab, Inc., WELLS BIO, Anagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
WuXi Diagnostics and Molecular Testing Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for WuXi Diagnostics, https://bouncewatch.com/company/wuxi-diagnostics, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes